clearing

Ethyl cinnamate has antifungal, and vasorelaxant effects. Ethyl cinnamate can lead to the damage of cell membrane system and metabolic disorder through inducing lipid peroxidation via initiating ROS overproduction. Ethyl cinnamate can inhibit the tonic contractions induced by high K+ and phenylephrine (PE) in a concentration-dependent manner, with respective IC50 values of 0.30 mM and 0.38 mM.

Dichlorophen (DDM) is a nontoxic laxative vermicide of chlorinated phenol compound. Dichlorophen is used as a veterinary fungicide, anthelmintic, and anti-protozoan, as well as an ingredient in antimicrobial soaps and shampoos. This agent probably acts by increasing the clearing of intestinal contents, thereby eradicating tapeworm infections from the intestines.

Ferroleuton is a selective competitive inhibitor of 5-lipoxygenase with an IC50 of 0.21 μM. It demonstrates antioxidant properties, clearing 86% of DPPH at 50 μM and exhibiting activities in ABTS (EC50 = 19.42 μM) and FRAP (EC50 = 3.32 μM) assays.

GL392 is a senolytic agent that delivers the potent senescence-clearing compound Dasatinib specifically to senescent cells. By targeting the LBD domain, it binds lipofuscin in these cells and releases Dasatinib via an ester linkage, inducing apoptosis (Apoptosis) in senescent cells. Additionally, GL392 is encapsulated in PEO-b-PCL microcapsules to ensure efficient intracellular delivery while minimizing systemic toxicity. GL392 is applicable in cancer research.

Dasatinib derivative 1 (2e) effectively releases nitric oxide (NO) and increases the concentration of 3’,5’-cyclic guanosine monophosphate (cGMP), while maintaining senescent cell-clearing activity. This compound can be utilized for research into chronic ocular hypertension (COHT) glaucoma.

Raloxifene alkene (Compound 101) is a significant serum cholesterol-clearing agent. It exhibits notable antiproliferative activity against breast cancer cells. In an ovariectomized rat model, Raloxifene alkene effectively reduces serum cholesterol levels without significantly increasing uterine weight or the number of eosinophils in stromal cells. This compound is applicable for research into postmenopausal syndrome, particularly osteoporosis, estrogen-dependent breast cancer, and uterine cancer.

1. Cistanoside A possesses protective activities on CCl4 induced hepatotoxicity in mice, which is involved with increasing free radicals clearing activities, alleviating lipid-overoxidation damage, and improving respiratory chain function in mitochondria.

Primaquine is an antimalarial compound and a gametocytocide, clearing liver schizonts and dormant forms of Plasmodium vivax.

Eupalinolide A has the effects of relieving phlegm and relieving cough, clearing away heat and detoxification, diuretic swelling and reducing blood pressure.

Maftivimab (REGN3470-3471-3479), also known as Atoltivimab, Odesivimab (Inmazeb), is a Filovirus inhibitor and a Food and Drug Administration (FDA)-approved agent for the research of Zaire ebolavirus infection [1].

Briquilimab (JSP-191) is a humanized, aglycosylated monoclonal antibody that directly inhibits the interaction between the stem cell factor (SCF) ligand and its receptor, KIT (CD117), leading to the blockade of the downstream KIT signaling pathway and ultimately inducing mast cell apoptosis; the SCF-KIT interaction is well-characterized as essential for mast cell survival, and its inhibition has been demonstrated to directly trigger mast cell apoptosis primarily through the Bim-mediated pathway, thereby removing the underlying cellular source of inflammation for many immunological and inflammatory diseases, including chronic urticaria and asthma.

KP-302 (compound 23) is a selective protein arginine deaminase 2 (PAD2) inhibitor with a Ki of 60 μM, capable of reversing physical disability in multiple sclerosis (MS) mice and clearing T-cell infiltration in the brain.

Anti-CD7 Antibody is a monoclonal antibody specifically recognizing the CD7 surface antigen, which is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and some acute myeloid leukemias. This antibody is primarily used for developing targeted therapeutic strategies, such as antibody-drug conjugates (ADCs) or nanobody drugs, aimed at precisely clearing malignant T-lymphocytes while minimizing toxicity to normal hematopoietic stem cells.

Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody that targets hepatitis B surface antigen (HBsAg). It exhibits significant antiviral activity by neutralizing and clearing HBV and HDV, as well as eliminating subviral particles containing HBsAg. Brelovitug is applicable for research on HDV and HBV infections, chronic hepatitis D (CHD), and chronic hepatitis B (CHB).

Dalidnetug is a humanized monoclonal antibody that targets human β-amyloid precursor protein (APP). By specifically binding to APP, Dalidnetug reduces the production of β-amyloid (Aβ), thereby demonstrating activity in clearing β-amyloid. This compound holds potential for research in Alzheimer's disease.

Ethyl cinnamate-d5 is the deuterated form of Ethyl cinnamate. Often used as a component in various fragrance compounds, Ethyl cinnamate serves as a flavoring agent in food and cosmetic additives. Additionally, it acts as an excellent clearing agent for mammalian tissues.

Ethyl Cinnamate (Standard) is the certified analytical standard of Ethyl cinnamate intended for research and analytical applications, and Ethyl cinnamate is an orally active constituent of Kaempferia galanga rhizomes that exhibits anticancer, nematocidal, sedative, vasorelaxant, fragrance, and tissue-clearing properties, suppresses colorectal tumor growth via VEGFR2 pathway–mediated anti-angiogenesis, and inhibits high potassium- and phenylephrine-induced tonic contractions in rat aorta with IC50 values of 0.30 mM and 0.38 mM, respectively.

Eupalinolide B (Standard) is a reference standard for research and analysis in studies involving Eupalinolide B. Eupalinolide A has the effects of relieving phlegm and relieving cough, clearing away heat and detoxification, diuretic swelling and reducing blood pressure.